PSCA-Targeted BPX-601 CAR T Cells with Pharmacological Activation by Rimiducid in Metastatic Pancreatic and Prostate Cancer: A Phase I Dose Escalation Trial

Investigators reported results of a Phase I open-label, dose-escalation trial of BPX-601, an investigational autologous prostate stem cell antigen (PSCA)-directed GoCAR-T® cell product containing an inducible MyD88/CD40 ON-switch responsive to the activating dimerizer rimiducid, in patients with metastatic CRPC.